Q-omics provides the consensus-scored LINC00173 profile across patient tissues and cancer cell-line models. LINC00173 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC00173 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC00173 RNA expression shows 16,835 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where LINC00173 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00173 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00173 survival associations across molecular data types. LINC00173 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00173 RNA expression–survival associations across cancer types. High LINC00173 expression shows unfavorable associations in UCEC, KICH and LIHC, but favorable associations in MESO, HNSC and STAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC00173 RNA expression.
This table summarizes LINC00173 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00173. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00173 shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRC, LIHC, COAD and LUSC. The KIRC box plot shows higher LINC00173 RNA expression in tumor versus normal tissue (log2 FC = +1.261, t-test p < 0.001).
This table shows molecular features associated with LINC00173 in patient tissues and cancer cell lines. In patient samples, LINC00173 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
